One of the first human studies investigating a responsiveness of exogenous s.c. leptin administration using recombinant methionyl human leptin (r-metHuLeptin) presented relevant weight and fat mass loss in patients with obesity and elevated endogenous serum leptin concentrations after an initial treatment period of four weeks [77]. This evidence concerns the gene LEP and obesity due to melanocortin 4 receptor deficiency.